All In Biotech

Drug Trial Radar · NCT03161353

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Last checked: Nov 20, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

377

Actual

Start

Jun 26, 2017

Primary completion

Nov 1, 2023

Study completion Nov 1, 2026

Sponsor

Lead sponsor
MedSIRAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla. And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.

Conditions

  • Breast Cancer

Interventions

  • PerjetaDrug

    All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.

  • HerceptinDrug

    All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.

  • DocetaxelDrug

    Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin

  • CarboplatinDrug

    Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.

  • LetrozoleDrug

    Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.

  • TamoxifenDrug

    Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy. Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the rate of pCRTime frame: After Cycle 6 or 8 (each cycle 21 days- After 4.2 or 5.6 months)
  2. 3-year iDFS rateTime frame: After 3 years (36 months)

Locations

56 sites in 7 countries. Site status is shown where the registry gives one.

  • Institute Jules Bordet

    Brussels, Belgium

  • CLCC d'Auvergne. Centre Jean Perrin.

    Clermont-Ferrand, France

  • Institute de Cancerologie de Laurraine

    Nancy, France

  • Groupe Hospitalier Diaconesses

    Paris, France

  • Hopital Tenon

    Paris, France

  • Hospital Georges Pompidou

    Paris, France

  • Centre Paul Strauss

    Strasbourg, France

  • Institut Claudius Régaud

    Toulouse, France

  • Kliniken Essen Mitte

    Essen, Germany

  • Klinikum der Med. Fakultät Halle

    Halle, Germany

  • National center for tumor disease NCT

    Heidelberg, Germany

  • Städtisches Klinikum "St. Georg" Leipzig

    Leipzig, Germany

  • Hämatologisch-Onkologische Schwerpunktpraxis

    München, Germany

  • Clinical of Nuclear Medicine Technical University Munich

    Munich, Germany

  • Ospedale Maggiore Bologna

    Bologna, Italy

  • Ospedale Antonio Perrino

    Brindisi, Italy

  • Istituto Ospedalieri di Cremona

    Cremona, Italy

  • Ospedale Mantova

    Mantua, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • Ospedale Guglielmo de Saliceto

    Piacenza, Italy

  • Hospital Senhora da Oliveira

    Guimarães, Portugal

  • Hospital Beatriz Angelo

    Lisbon, Portugal

  • Hospital da Luz

    Lisbon, Portugal

  • Hospital Fernando Fonseca

    Lisbon, Portugal

  • Centro Hospitalar Sao Joao

    Porto, Portugal

  • Hospital do Santo Antonio

    Porto, Portugal

  • Centro Hospitalaer de Tras-os-Montes e Alto Douro

    Vila Real, Portugal

  • Hospital Universitario A Coruña

    A Coruña, Spain

  • Hospital Vall D'Hebrón

    Barcelona, Spain

  • Hospital Clínic i Provincial de Barcelona

    Barcelona, Spain

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Reina Sofía

    Córdoba, Spain

  • ICO Girona

    Girona, Spain

  • Hospital Arnau de Vilanova

    Lleida, Spain

  • Hospital La Paz

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • CHUS Santiago de Compostela

    Santiago de Compostela, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Hospital Arnau de Vilanova

    Valencia, Spain

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.